How is coronavirus affecting our operations? Learn more


Diabetes drug slows experimental Parkinson’s disease progression, human trials to begin next year

A new investigational drug, MSDC-0160, originally developed for type 2 diabetes is being readied for human clinical trials in search of the world’s first treatment to impede the progression of Parkinson’s disease following publication of research findings in the journal Science Translational Medicine. “Until now, Parkinson’s treatments have focused on symptom management. If successful in…

Print this page Print this page

New growth factor indicates possible regenerative effects in Parkinson’s disease

Science Today reports that researchers at Lund University and Karolinska Institutet have, in a first-in-human clinical study with twelve participating patients, applied a growth factor to the brain with the hope of preserving dopaminergic cells and fibres. The growth factor, PDGF (platelet-derived growth factor), has previously demonstrated, in studies in animals with Parkinson-like symptoms, reparative…

Print this page

Drug candidates may block cell death in Parkinson’s disease

Science Daily reports that in a pair of related studies, scientists from the Florida campus of The Scripps Research Institute (TSRI) have shown their drug candidates can target biological pathways involved in the destruction of brain cells in Parkinson’s disease. The studies, published in the Journal of Medicinal Chemistry and Scientific Reports, suggest that it…

Print this page

Phase III trial of Israpidine

Researchers at the University of California, San Diego School of Medicine have launched a Phase III clinical trial to evaluate the drug isradipine, a calcium channel blocker often used to treat high blood pressure, as a potential new treatment for Parkinson disease (PD). The goal of the study is to determine whether the drug can…

Print this page

PBT434 Drug Shows Promise

Researchers at the University of Leeds are one step closer to developing a new treatment for Parkinson’s, thanks to a £150,000 research grant from Parkinson’s UK. This new research will allow Dr James Duce and his team to investigate whether a drug known as PBT434 that targets iron may have potential as a new and…

Print this page
Back to top